ArticleStroke (Hoboken, N.J.)2025
Safety and Efficacy of the Bimodal Armadillo Catheter for Intracranial Interventions via the Transfemoral Approach.
Article in Stroke (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Radial-specific catheters for neuroendovascular procedures: A systematic review and meta-analysis.Neurosurgical review · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Armadillo (Q'Apel Medical Inc., Fremont, CA) is a novel bimodal guide catheter, combining properties of a long support sheath with a large-bore distal access catheter, whose stiffness can be adjusted from "track" mode during navigation to "support" mode for intervention. The main objective of this study was to determine the safety and efficacy of the Armadillo for intracranial interventions via the transfemoral approach. Methods: This is a retrospective study of our initial Armadillo experience, composed of all patients who underwent an intracranial intervention using the Armadillo via the transfemoral route, between December 2022 and December 2023, at a single institution. Transvenous, external carotid, and stroke-related interventions were excluded. Results: Of 62 total interventions with the Armadillo catheter, 58 procedures (53/58 [91.4%] for aneurysms, 3/58 [5.6%] for arteriovenous malformations, and 2/58 [3.4%] for intracranial stenosis) in 55 patients (mean age, 57.2 [standrad deviation (SD), 12.4] years; 46/55 [83.6%] female sex) met study criteria. Most interventions were in the anterior circulation (51/58 [87.9%]) and significant carotid or vertebral artery tortuosity was encountered in 10 of 58 (17.2%) cases. The Armadillo was the primary sheath in 57/58 (98.3%) cases, and 50/58 (86.2%) received vasodilator for vasospasm prophylaxis prior to distal navigation. The Armadillo was successfully navigated to the intended target location in 52 of 58 (89.7%) procedures, predominantly over a macro-guidewire alone (41/58 [70.7%]). The need for a triaxial system during the intervention was obviated in 36 of 58 (62.1%) procedures, and all interventions were completed successfully without having to exchange for an alternate support catheter. There were no Armadillo-related complications. Conclusion: The Armadillo was highly effective as a long guide sheath for intracranial interventions via the transfemoral route, with a high rate of successful distal navigation and no device-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.